comprehensive -WSS

comprehensive

author：focus 2025-10-02 21:04:49 - browse：6

Adam's take main illustration — Molly Ferguson/STAT

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

A Worst CEO gets some much-needed help

For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Appeals court upholds limits to abortion pill

focus

WSS

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

2024 GOP presidential candidates spar over abortion in debate

Pandemic and All Hazards Preparedness Act needs lean update

Eisai exec who led development of Alzheimer’s drug to retire

Eisai exec who led development of Alzheimer’s drug to retire

Pandemic and All Hazards Preparedness Act needs lean update

focus

comprehensive

A Worst CEO gets some much-needed help

explore

After affirmative action ruling, medical educators look to 'holistic review'

In science, is the line between industry and academia shifting?

Psychedelics group wrestles with new pharma identity

Teachers share how revamped forgiveness program helped with their student loans

Affirmative action in medical school literally saved lives

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Virginia high school admissions case could be legal follow

Complete sequence of Y chromosome published for first time

knowledge

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

ACA's risk program benefits Blue Cross Blue Shield insurers

Medicare wants to send $9 billion to 340B hospitals

As pharma fights Medicare drug negotiation, hospitals, docs silent

Appeals court upholds limits to abortion pill

Eisai exec who led development of Alzheimer’s drug to retire

leisure time

entertainment

focus

focus